LINEBURG


<< . .

 10
( 30)



. . >>

to the ovarian hyperstimulation syndrome. Hum Reprod 11:1381À6.
Abramov Y, Barak V, Nisman B et al. (1997). Vascular endothelial growth factor plasma
levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome.
Fertil Steril 67:261À5.
Abramov Y, Naparstek Y, Elchalal U et al. (1999). Plasma immunoglobulins in patients
with severe ovarian hyperstimulation syndrome Fertil Steril 71:102À5.
Abramov Y, Schenker JG, Lewin A et al. (2001). Soluble ICAM-1 and E-selection levels
correlate with clinical and biological aspects of severe ovarian hyperstimulation
syndrome. Fertil Steril 76:51À7.
Adashi EY (1990). The potential relevance of cytokines to ovarian physiology: the
emerging role of resident ovarian cells of the white blood cell series. Endocr Rev
11:454À64.
Agrawal R, Conway G, Sladkevicius P et al. (1998). Serum vascular endothelial growth
factor and Doppler blood ¬‚ow velocities in in vitro fertilization: relevance to ovarian
hyperstimulation syndrome and polycystic ovaries. Fertil Steril 79:651À8.
Agrawal R, Tan SL, Wild S et al. (1999). Serum vascular endothelial growth factor
concentrations in in vitro fertilization cycles predict the risk of ovarian
hyperstimulation syndrome. Fertil Steril 71:278À93.
Albert C, Garrido N, Mercader A et al. (2002). The role of endothelial cells in the
pathogenesis of ovarian hyperstimulation syndrome. Mol Hum Reprod 8:409À18.
Alonso-Muriel I, Gomez-Gallego R, Pau E et al. (2005). Free VEGF but not total VEGF is
responsible for ovarian hyperstimulation syndrome (OHSS) onset. J Soc Gyn Invest 12
(Suppl 6):87A.
Ando H, Furugori K, Shibata K et al. (2003). Dual renin-angiotensin blockade therapy in
patients at high risk of early ovarian hyperstimulation syndrome recieving IVF and
elective embryo cryopreservation: a case series. Hum Reprod 18:1219À22.
Artini PG, Fasciani A, Monti M et al. (1998) Changes in vascular endothelial growth factor
concentrations and the risk of ovarian hyperstimulation syndrome in women
enrolled in an in vitro fertilization program. Fertil Steril 70:560À4.
Asch RH, Li HP, Balmeceda JP et al. (1991). Severe ovarian hyperstimulation syndrome in
assisted reproductive technology; de¬nition of high risk groups. Hum Reprod
6:1395À9.
Balasch J, Carmona F, Llach J et al. (1990). Acute prerenal failure and liver dysfunc-
tion in a patient with severe ovarian hyperstimulation syndrome. Hum Reprod
5:348À51.
Balasch J, Arroyo V, Carmona F et al. (1991). Severe ovarian hyperstimulation syndrome:
role of peripheral vasodilation. Fertil Steril 56:1077À83.
Balasch J, Arroyo V, Fabregues F et al. (1994). Neurohormonal and hemodynamic
changes in severe cases of ovarian hyperstimulation syndrome. Ann Intern Med
121:27À33.
71
REFERENCES




Barak V, Mordel N, Zakicek G et al. (1992). The correlation between interleukin 2 and
interleukin 2 receptors to oestradiol, progesterone and testosterone levels in
preovulatory follicles of in vitro fertilization patients. Hum Reprod 7:926À9.
Barak V, Elchalal U, Edelstein M et al. (2004). Interleukin-18 levels correlate with severe
ovarian hyperstimulation syndrome. Fertil Steril 82:415À20.
Banarjee SK, Sarkar DK, Weston AP et al. (1997). Over expression of vascular endothelial
growth factor and its receptors during the development of estrogen induced rat
pituitary tumors may mediate estrogen-initiated tumor angiogenesis. Carcinogenesis
18:1155À61.
Ben-Rafael Z & Orvieto R (1992). Cytokines-involvement in reproduction. Fertil Steril
58:1093À9.
Blankestijn PF, Derkx FHM, Van Geelen JA et al. (1990). Increase in plasma prorenin
during the mesntrual cycle of a bilaterally nephrectomized woman. Br J Obstet
Gynaecol 97:1038À42.
Borenstein R, Elhalah U, Lunenfeld B & Schwartz ZS (1989). Severe ovarian
hyperstimulation syndrome: a reevaluated therapeutic approach. Fertil Steril
51:791À5.
Buyalos RP, Watson JM, Martinez Maza O et al. (1992). Detection of IL-6 in human
follicular ¬‚uid. Fertil Steril 57:1230À40.
Castelbaum AJ, Bigdeli H, Post KD et al. (2002). Exacerbation of ovarian hyperstimulation
by leuporlide reveals a gonadotroph adenoma. Fertil Steril 78:1311À3.
Catargi B, Felicie-Dellan E & Tabarin A (1999). Comment on gonadotrophin adenoma
causing ovarian hyperstimulation. J Clin Endocrinol Metab 84:3404À6.
Chae HD, Park EJ, Kim SH et al. (2001). Ovarian hyperstimulation syndrome
complicating a spontaneous singleton pregnancy: a case report. J Assist Reprod
Genet 18:120À3.
Charnock-Jones DS, Sharkey AM, Rajput-Williams J et al. (1993). Identi¬cation and
localization of alternately spliced mRNAs for vascular endothelial growth factor in
human uterus and estrogen regulation in endometrial carcinoma cell line. Biol Reprod
48:1120À60.
Chen CD, Wu MY, Chen HF et al. (2000). Relationships of serum pro-in¬‚ammatory
cytokines and vascular endothelial growth factor with liver dysfunction in severe
ovarian hyperstimulation syndrome. Hum Reprod 15:66À71.
Christin-Maitre S, Rongieres-Bertrand C, Kottler ML et al. (1998). A spontaneous and
severe hyperstimulation of the ovaries revealing a gonadotroph adenoma. J Clin
Endocrinol Metab 83:3450À3.
Cohen T, Hahari D, Cerem-Weiss L et al. (1996). Interleukin-6 induces the expression of
vascular endothelial growth factor. J Biol Chem 271:736À41.
Connolly DT, Olander JV, Heuvelman D et al. (1989). Human vascular permeability
factor. Isolation from U937 cells. J Biol Chem 264:20017À24.
Culler MD, Tarlatzis BC, Rzasa PJ et al. (1986). Renin-like activity in ovarian follicular
¬‚uid. J Clin Endocrinol Metab 62:613À5.
Cunha-Filho JS, Lemos N, Stein N et al. (2005). Vascular endothelial growth factor and
inhibin A in follicular ¬‚uid of infertile patients who underwent in vitro fertilization
with a gonadotropin-releasing hormone antagonist. Fertil Steril 83:902À7.
D™Ambrogio G, Fasciani A, Monti M et al. (1999). Serum vascular endothelial growth
factor levels before starting gonadotrophin treatment in women who have developed
moderate forms of ovarian hyperstimulation syndrome. Gynecol Endocrinol
13:311À15.
Damas P, Ledoux D, Nys M et al. (1992). Cytokine serum level during severe sepsis in
humans IL-6 as a marker of severity. Ann Surg 215:356À62.
Daniel Y, Geva E, Amit A et al. (1999). Levels of soluble vascular cell adhesion molecule-1
and soluble intercellular adhesion molecule-1 are increased in women with ovarian
hyperstimulation syndrome. Fertil Steril 71:896À901.
72 PATHOPHYSIOLOGY OF OVARIAN HYPERSTIMULATION SYNDROME




Daniel Y, Geva E, Amit A et al. (2001). Soluble endothelial and platelet selectins in serum
and ascitic ¬‚uid of women with ovarian hyperstimulation syndrome. Am J Reprod
Immunol 45:154À60.
Davison JM, Vallotton MV & Lindheimer MD (1981). Plasma osmolality and urinary con-
centration and dilution during and after pregnancy: evidence that lateral recombency
inhibits maximal urinary concentrating ability. Br J Obstet Gynaecol 88:472À9.
Davison JM, Gilmore EA, Durr J et al. (1984). Altered osmotic threshold for vasopressin
secretion and thirst in human pregnancy. Am J Physiol 246:F105À109.
Delbaere A, Bergmann PJM & Gervy-Decoster C (1994). Angiotensin II immunoreactivity
is elevated in ascites during severe ovarian hyperstimulation syndrome: implications
for pathophysiology and clinical management. Fertil Steril 62:731À7.
Delbaere A, Bergmann PJM, Gervy-Decoster C et al. (1997). Prorenin and active renin
concentrations in plasma and ascites during severe ovarian hyperstimulation
syndrome. Hum Reprod 12:236À40.
Delvigne A (2004). Epidemiology and pathophysiology of ovarian hyperstimulation
syndrome. In (Gerris G, Olivennes F & De Sutter P, Eds), Assisted Reproductive
Technologies: Quality and Safety. New York: Parthenon Publishing, Chapter 12,
pp. 149À62.
Derkx FHM, Stuenkel C, Schalekamp MPA et al. (1986). Immunoreactive renin, prorenin,
and enzymatically active renin in plasma during pregnancy and in women taking oral
contraceptives. J Clin Endocrinol Metab 63:1008À15.
Djerassi A, Coutifaris C, West VA et al. (1995). Gonadotroph adenoma in a
premenopausal woman secreting follicle-stimulating hormone and causing ovarian
hyperstimulation. J Clin Endocrinol Metab 80:591À4.
Do YS, Sherrod A, Lobo RA et al. (1988). Human ovarian theca cells are a source of renin.
Proc Natl Acad Sci USA 85:1957À8.
Donnez J, Langerock S & Thomas K (1982). Peritoneal ¬‚uid volume and 17b-estradiol and
progesterone concentrations in ovulatory, anovulatory, and postmenopausal women.
Obstet Gynecol 59:687À92.
El-Chalal U & Schenker JG (1997). The pathophysiology of ovarian hyperstimulation
syndrome À views and ideas. Hum Reprod 12:1129À37.
¨ ¨
Enskog A, Nilsson L & Branstrom M (2001a). Plasma levels of free vascular endothelial
growth factor165 (VEGF165) are not elevated during gonadotropin stimulation in
in vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome
(OHSS): results of a prospective cohort study. Eur J Obstet Gynecol Reprod Biol
96:196À201.
¨ ¨
Enskog A, Nilsson L & Branstrom M (2001b). Low peripheral blood levels of the
immunosuppressive cytokine interleukin-10 (IL-10) at the start of gonadotrophin
stimulation indicates increased risk for development of ovarian hyperstimulation
syndrome (OHSS). J Reprod Immunol 49:71À85.
Evbuomwan IO, Davison JM & Murdoch AP (2000). Coexistent hemoconcentration
and hypoosmolality during superovulation and in severe ovarian hyperstimulation
syndrome: volume homeostasis paradox. Fertil Steril 74:67À72.
Evbuomwan IO, Davison JM, Baylis PM et al. (2001). Altered osmotic thresholds for
arginine vasopressin secretion and thirst during superovulation and in the ovarian
hyperstimulation syndrome (OHSS): relevance to the pathophysiology of OHSS.
Fertil Steril 75:933À41.
Fernandez LA, Tarlatzis BC, Rzasa QJ et al. (1985a). Renin like activity in ovarian follicular
¬‚uid. Fertil Steril 44:219À23.
Fernandez LA, Twickler J & Mead A (1985b). Neovascularization produced by angiotensin
II. J Lab Clin Med 105:141À2.
Ferrara N & Henzel WJ (1989). Pituitary follicular cells secrete a novel heparin-binding
growth factor speci¬c for vascular endothelial cells. Biochem Biophys Res Commun
161:851À8.
73
REFERENCES




Ferrara N, Houck K, Jakeman L et al. (1992). Molecular and biological properties of the
vascular endothelial growth factor family of proteins. Endocr Rev 13:18À32.
Frederick JL, Shimanuki T & DiZerega GS (1984). Initiation of angiogenesis by human
follicular ¬‚uid. Science 224:389À92.
Friedlander MA, de Mola JR & Goldfarb JM (1993). Elevated levels of interleukin-6 in
ascites and serum from women with ovarian hyperstimulation syndrome. Fertil Steril
60:826À32.
Friedman CI, Seifer DB, Kennard EA et al. (1998). Elevated level of follicular ¬‚uid vascular
endothelial growth factor is a marker of diminished pregnancy potential. Fertil Steril
64:268À72.
Geva E, Amit A, Lessing JB et al. (1999). Follicular ¬‚uid levels of vascular endothelial
growth factor. Are the premarkers for ovarian hyperstimulation syndrome? J Reprod
Med 44:91À6.
Gitay-Goren H, Soker S, Vlodavsky I et al. (1992). The binding of vascular endothelial
growth factor to its receptors is dependent on cell surface-associated heparin-like
molecules. J Biol Chem 267:6093À8.
Glorioso N, Atlas SA, Laragh JH et al. (1986). Prorenin in high concentrations in human
ovarian follicular ¬‚uid. Science 233:1422À4.
Goad DL, Rubin J, Wang H et al. (1996). Enhanced expression of vascular endothelial
growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced
by insulin-like growth factor I. Endocrinology 137:2262À8.
Goldsman MP, Pedram A, Dominguez CE et al. (1995). Increased capillary permeability
induced by human follicular ¬‚uid: a hypothesis for an ovarian origin of the
hyperstimulation syndrome. Fertil Steril 63:268À72.
Gomez R, Simon C, Remohi J et al. (2002). Vascular endothelial growth factor receptor-2
activation induces vascular permability in hyperstimulated rats, and this effect is
prevented by receptor blockade. Endocrinology 143:4338À49.
Gomez R, Simon C, Remohi J et al. (2003). Administration of moderate and high doses of
gonadotropins to female rats increases ovarian vascular endothelial growth factor
(VEGF) and VEGF receptor-2 expression that is associated to vascular hyperperme-
ability. Biol Reprod 299:2164À71.
Gomez R, Lima I, Simon C & Pellicer A (2004). Administration of low-dose
LH induces ovulation and prevents vascular hyperpermeability and vascular
endothelial growth factor expression in superovulated rats. Reproduction
127:483À9.
Gordon JD, Mesiano S, Zaloudek CJ et al. (1996). Vascular endothelial growth factor
localization in human ovary and fallopian tubes: possible role in reproductive
function and ovarian cyst formation. J Clin Endocrinol Metab 81:353À9.
Gospodarowicz D, Abraham JA & Schilling J (1989). Isolation and characterization of
a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate
cells. Proc Natl Acad Sci 86:7311À5.
Handin RI & Wagner KK (1989). Molecular and cellular biology of von Willebrand
factor. In (Coller BS, Ed.), Progress in Hemostasis and Thrombosis. Philadelphia:
WB Saunders, Vol. 9, p. 233.
Haning RV, Estil Y & Nolten WE (1985). Pathophysiology of the ovarian hyperstimulation
syndrome. Obstet Gynecol 66:220À4.
Hsueh WA, Carlson EJ & Dzau VJ (1983). Characterization of inactive renin from human
kidney and plasma: evidence of a renal source of circulating inactive renin. J Clin
Invest 71:506À9.
Itskovitz J & Sealey JE (1987). Ovarian prorenin-renin-angiotensin system. Obstet Gynecol
Surv 42:545À9.
Itskovitz J, Bruneval P, Soubrier F et al. (1992). Localization of renin gene expression
in monkey ovarian theca cells by in situ hybridization. J Clin Endocrinol Metab
75:1374À80.
74 PATHOPHYSIOLOGY OF OVARIAN HYPERSTIMULATION SYNDROME




Kaiser UB (2003). The pathogenesis of the ovarian hyperstimulation syndrome. New Engl J
Med 349:729À32.
Kamat BR, Brown LF, Manseau EJ et al. (1995). Expression of vascular permeability
factor/vascular endothelial growth factor by human granulosa and theca lutein cells.
Am J Pathol 146:157À65.
Katz Z, Lancet M, Borenstein R et al. (1984). Absence of teratogenicity of indomethacin in
ovarian hyperstimulation syndrome. Int J Fertil 29:186À8.
Keck PJ, Hauser SD, Krivi G et al. (1989). Vascular permeability factor, an endothelial cell
mitogen related to PDGF. Science 246:1309À12.
Kendall RL & Thomas KA (1993). Inhibition of vascular endothelial cell growth factor
activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA
90:10705À9.
Kim KJ, Li B, Winer J et al. (1993). Inhibition of vascular endothelial growth factor
induced angiogenesis suppresses tumor growth in vivo. Nature 362:841À4.
Kishimoto T (1989). The biology of IL-6. Blood 74:1À10.
Kitajima Y, Endo T, Manase K et al. (2004). Gonadotropin-releasing hormone agonist
administration reduced vascular endothelial growth factor (VEGF), VEGF recep-
tors, and vascular permeability of the ovaries of hyperstimulated rats. Fertil Steril
81(Suppl 2):842À9.
Koch AE, Harlow LA, Haines GK et al. (1994). Vascular endothelial growth factor: a
cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152:
4149À56.
Krasnow JJ, Berga SL, Guzick DS et al. (1996). Vascular permeability factor and vascular
endothelial growth factor in ovarian hyperstimulation syndrome. Fertil Steril
65:552À5.
Kwekkeboom DJ, de Jong FH & Lamberts SW (1989). Gonadotrophin release by clinically
nonfunctioning and gonadotroph pituitary adenomas in vivo and in-vitro: relation to
sex and effects of thryotropin-releasing hormone, gonadotrophin-releasing hormone,
and bromocriptine. J Clin Endocrinol Metab 68:1128À35.
Lee A, Christenson LK, Stouffer RL et al. (1997). Vascular endothelial growth factor levels
in serum and follicular ¬‚uid of patients undergoing in-vitro fertilization. Fertil Steril
68:305À11.
Leung DW, Cachianes G, Kuang WJ et al. (1989). Vascular endothelial growth factor is
a secreted angiogenic mitogen. Science 246:1306À9.
Levin I, Gamzu R, Hasson Y et al. (2004). Increased erythrocyte aggregation in ovarian
hyperstimulation syndrome: a possible contributing factor in the pathophysiology of
this disease. Hum Reprod 19:1076À80.
Levy T, Oriveto R, Homburg R et al. (1996). Severe ovarian hyperstimulation syndrome
despite low plasma oestrogen concentrations in a hypogonadotrophic, hypogonadal
patient. Hum Reprod 11:1177À9.
Li J, Perrella MA, Tsai JC et al. (1995). Induction of vascular endothelial growth factor
gene expression by interleukin-1 beta in rat aotic smooth muscle cells. J Biol Chem
270:308À12.
Lightman A, Tarlatzis BC, Rzasa PJ et al. (1987). The ovarian reninÀangiotensin system:
renin-like activity and angiotensin II/III immunoreactivity in gonadotropin-
stimulated human follicular ¬‚uid. Am J Obstet Gynecol 156:808À16.
Loret de Mola JR, Flores JP, Baumgardner GP et al. (1996a). Elevated interleukin-6 levels
in the ovarian hyperstimulation syndrome: ovarian imunohistochemical localization
of interleukin-6 signal. Obstet Gynecol 87:581À7.
Loret de Mola JR, Baumgardner GP, Goldfarb JM et al. (1996b). Ovarian hyperstimulation
syndrome: pre-ovulatory serum concentrations of interleukin-6, interleukin-1
receptor antagonist and tumor necrosis factor cannot predict its occurrence. Hum
Reprod 11:1377À80.
75
REFERENCES




Ludwig M, Gembruch U, Bauer O et al. (1998). Ovarian hyperstimulation syndrome
(OHSS) in a spontaneous pregnancy with a fetal and placental triploidy: information
about the general pathophysiology of OHSS. Hum Reprod 13:2082À7.
Ludwig M, Jekmann W, Bauen O et al. (1999). Prediction of severe ovarian hyper-
stimulation by free serum vascular endothelial growth factor concentration on the
day of human chorionic gonadotropin administration. Hum Reprod 14:2437À41.
Maathuis JB, Van Look PF & Michie EA (1978). Changes in volume, total protein and
ovarian steroid concentrations of peritoneal ¬‚uid through the human menstrual
cycle. J Endocrinol 76:123À4.
Mannucci PM, Canciani MT, Rota L et al. (1981). Response of factor VIII/von Willebrand
factor to DDAVP in healthy subjects and patients with haemophilia A and von
Willebrand™s disease. Br J Hematal 47:283À93.
Manolopoulos K, Lang U, Gips H et al. (2001). Elevated interleukin-10 and sex steroid
levels in peritoneal ¬‚uid of patients with ovarian hyperstimulation syndrome. Eur J
Obstet Gynecol Reprod Biol 99:226À31.
Mantovani A, Bussolino F & Introna M (1997). Cytokine regulation of endothelial cell
function: from molecular level to the bedside. Immunol Today 18:231À40.
Mathur RS, Jenkins JM & Bansal AS (1997). The probable role of the immune system in
the pathogenesis of ovarian hyperstimulation syndrome. Hum Reprod 12:2629À34.
McClure N, Healy DL, Rogers PA et al. (1994). Vascular endothelial growth factor
as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet
344:235À6.
McElhinney B, Ardill J, Caldwell C et al. (2002). Variations in serum vascular endothelial
growth factor binding pro¬les and the development of ovarian hyperstimulation
syndrome. Fertil Steril 78:286À90.
McLaren J, Prentice A, Charnock-Jones DS et al. (1996). Vascular endothelial growth
factor (VEGF) concentrations are elevated in peritoneal ¬‚uid of women with
endometriosis. Hum Reprod 11:220À3.
Meyer D, Pietu G, Fressinaud E et al. (1991). Von Willebrand factor: structure and
function. Proc Mayo Clin 66:516À23.
Millauer B, Wizigmann-Voos S, Schnurch H et al. (1993). High af¬nity VEGF binding and
developmental expression suggest FLK-1 as a major regulator of vasculogenesis and
angiogenesis Cell 72:835À46.
Morris RS, Wong IL, Kirkham E et al. (1995). Inhibition of ovarian-derived prorenin to
angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum
Reprod 10:1355À8.
Motro B, Itin A, Sacjs L et al. (1990). Pattern of IL-6 gene expression in vivo suggests a role
for this cytokine in angiogenesis. J Cell Biol 87:3092À6.
Navot D, Margalioth E & Laufer N (1987). Direct correlation between plasma renin
activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 48:57À61.
Neufeld G, Cohen T, Gengrinovitch S et al. (1999). Vascular endothelial growth factor
(VEGF) and its receptors. The FASEB Journal 13:9À22.
Neulen J, Yan Z, Raczek S et al. (1995a). Ovarian hyperstimulation syndrome: vascular
endothelial growth factor/vascular permeability factor from luteinized granulosa cells
is the patho-physiological principle. In Abstracts of the 11th Annual Meeting of the
ESHRE, Hamburg.
Neulen J, Yan Z, Raczek S et al. (1995b). Human chorionic gonadotropin-dependent
expression of vascular endothelial growth factor/vascular permeability factor in
human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin
Endocrinol Metab 80:1967À71.
Novella-Maestre E, Gomez-Gallego R, Alonso-Muriel I et al. (2005). Progesterone has
no role in the increased vascular permeability which onsets OHSS. J Soc Gyn Invest 12
(Suppl 364):202A.
76 PATHOPHYSIOLOGY OF OVARIAN HYPERSTIMULATION SYNDROME




Ogawa S, Minakami H, Araki S et al. (2001). A rise of the serum level of von Willebrand
factor occurs before clinical manifestation of the severe form of ovarian hyper-
stimulation syndrome. J Assist Reprod Genet 18:114À19.
Ohba T, Ujioka T, Ishikawa K et al. (2003). Ovarian hyperstimulation syndrome-model
rats; the manifestation and clinical implication. Mol Cell Endocrinol 202:47À52.
Ong ACM, Eisen V, Rennie DP et al. (1991). The pathogenesis of the ovarian hyperstimu-
lation syndrome (OHS): a possible role for ovarian renin. Clin Endocrinol 34:43À9.
Oppenheim JJ, Ruscetti FW & Faltynek C (1991). Cytokines. In (Stites DP, Terr AI, Eds),
Basic and Clinical Immunology (7th Edn). East Norwalk, CT: Appleton and
Lange, p. 78.
Orvieto R, Voliovitch I, Fishman P et al. (1995). Interleukin-2 and ovarian
hyperstimulation syndrome: a pilot study. Hum Reprod 10:24À7.
Paulson RJ, Do YS, Hsueh WA et al. (1989). Ovarian renin production in vitro and in
vivo: characterization and clinical correlation. Fertil Steril 51:634À8.
Peach MJ (1977). Renin-angiotensin system: biochemistry and mechanism of action.
Physiol Rev 57:313À7.
Pellicer A, Palumbo A, DeCherney AH et al. (1988). Blockage of ovulation by an
angiotensin antagonist. Science 240:1660À1.
Pellicer A, Miru F, Sampaia M et al. (1991). In-vitro fertilization as a diagnostic and thera-
peutic tool in a patient with partial 17, 20 desmolase de¬ciency. Fertil Steril 55:970À5.
Pellicer A, Albert C, Mercader A et al. (1999). The pathogenesis of ovarian
hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1b,
interleukin-6, and vascular endothelial growth factor. Fertil Steril 71:482À9.
Penz-Vidovic I, Skori T, Grubisi G et al. (2000). Evolution of clinical symptoms in a young
woman with a recurrent gonadotroph adenoma causing ovarian hyperstimulation.
Eur J Endocrinol 143:607À14.
Pepperell JR, Nemeth G, Plaumbo A et al. (1993). The intraovarian reninÀangiotensin
system. In (Adashi EY, Leung PCK, Eds), The Ovary. New York: Raven Press,
pp. 363À80.
Phillips HS, Hains J, Leung DW et al. (1990). Vascular endothelial cell growth factor is
expressed in rat corpus luteum. Endocrinology 127:965À7.
Polishuk WZ & Schenker JG (1969). Ovarian overstimulation syndrome. Fertil Steril
20:443À5.
Pride SM, Ho Yuen B, Moon YS et al. (1986). Relationship of gonadotrophin-releasing
hormone, danazol and prostaglandin blockage to ovarian enlargement and ascites
formation of the ovarian hyperstimulation syndrome. Am J Obstet Gynecol
154:1155À60.
Pride SM, James C & Ho Yuen B (1990). The ovarian hyperstimulation syndrome. Semin
Reprod Endocrinol 8:247À60.
Ravindranath N, Little-Ihrig LL, Phillios HS et al. (1992). Vascular endothelial growth
factor messenger ribonucleic acid expression in the primate ovary. Endocrinol 131:
254À60.
Revel A, Barak V, Lavy Y et al. (1996). Characterization of intraperitoneal cytokines and
nitrites in women with severe ovarian hyperstimulation syndrome. Fertil Steril
66:66À71.
Rizk B (1992). Ovarian hyperstimulation syndrome. In (Brinsden PR, Rainsbury PA, Eds),
A Textbook of In-Vitro Fertilization and Assisted Reproduction. Carnforth, UK:
Parthenon Publishing, Chapter 23, pp. 369À83.
Rizk B (1993a). Ovarian hyperstimulation syndrome. In (Studd J, Ed.), Progress in
Obstetrics and Gynecology, Volume 11. Edinburgh: Churchill Livingstone, Chapter 18,
pp. 311À49.
Rizk B (1993b). Prevention of ovarian hyperstimulation syndrome: the Ten Command-
ments. European Society of Human Reproduction and Embryology Symposium,
Tel Aviv, Israel, pp. 1À2.
77
REFERENCES

<< . .

 10
( 30)



. . >>

Copyright Design by: Sunlight webdesign